Gyeunghaeng Hur

Dr. Gyeunghaeng Hur

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 July 2020 in bioRxiv
Verified
Preprint
Open access
PDF file
SGSe Hun Gu
Se Hun Gu
CYChi Ho Yu
Chi Ho Yu
YSYoungjo Song
Youngjo Song
NKNa Young Kim
Na Young Kim
ESEuni Sim
Euni Sim
SJSeong Tae Jeong
Seong Tae Jeong
A small interfering RNA (siRNA) inhibitors have demonstrated the novel modality for suppressing infectious diseases. Sixty-one siRNA molecules, predicted by the bioinformatics programs, were screened for the possibility of treating severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) using an in vitro plaque assay. Among six siRNA leads with the efficacy of reducing plaque number, the siRNA targeting RNA-dependent RNA polymerase (RdRp) showed a reduction in SARS-CoV-2 infection-induced fever and virus titer in the Golden Syrian hamster and rhesus macaque. These results suggest the potential for RdRp targeting siRNA as a new treatment for the coronavirus disease 2019 (COVID-19).

20 October 2017 in Acta Crystallographica Section F Structural Biology Communications
Verified
Journal Article
Open access
PDF file
WJWoo Hyeon Jeong
Woo Hyeon Jeong
DSDong Hyun Song
Dong Hyun Song
GHGyeunghaeng Hur
Gyeunghaeng Hur
SJSeong Tae Jeong
Seong Tae Jeong
Four mutations (N23A, Y90A, R110A and F177A) were introduced into S19, a vaccine candidate for staphylococcal enterotoxin B (SEB), resulting in a lower binding affinity towards the T-cell receptor beta chain (TCB) and reducing its superantigen activity. The structure of S19 was solved and was superposed on the native or complex structure of SEB. In the superposition model, mutations that were introduced seemed to reduce the number of hydrogen bonds at the SEB–TCB interface. S19 also displayed an unexpected structural change around the flexible-loop region owing to the Y90A mutation. This local structural change provided evidence that the mutated form of S19 could have a lower affinity for major histocompatibility complex (MHC) class II than wild-type SEB.

5 April 2024 in Journal of the Korea Institute of Military Science and Technology
Verified
Journal Article
Open access
PDF file
HYHyeongseok Yun
Hyeongseok Yun
HJHae-Eun Joe
Hae-Eun Joe
DSDong Hyun Song
Dong Hyun Song
CYChi Ho Yu
Chi Ho Yu
YSYoung-Jo Song
Young-Jo Song
GHGyeunghaeng Hur
Gyeunghaeng Hur

14 March 2025 in Toxins
Verified
Journal Article
Open access
PDF file
CYChi Ho Yu
Chi Ho Yu
YSYoung-Jo Song
Young-Jo Song
DSDong Hyun Song
Dong Hyun Song
HJHAE EUN JOE
HAE EUN JOE
CKChanghwan Kim
Changhwan Kim
GHGyeunghaeng Hur
Gyeunghaeng Hur
Botulinum neurotoxins (BoNTs) are the most potent toxins on Earth and are classified as Category A biological agents. BoNTs lead to paralysis in humans and cause botulism. Antibody therapeutics can effectively treat toxin-mediated infectious diseases. In this study, we generated a pharmaceutical humanized monoclonal antibody (HZ45 mAb) to prevent or treat botulism. HZ45 binds to the heavy chain receptor (HCR) domain of the toxin, preventing the toxin from entering the cell. The mAb was produced using hybridoma technology and phage display. We evaluated HZ45 mAb for the neutralization of BoNT serotype A (BoNT/A) in mice and rabbits. The survival results showed that pretreatment with HZ45 mAb provided 100% protection at a dose of 0.1 mg per mouse against a maximum of 100 LD50 of BoNT/A. To assess the therapeutic efficacy of HZ45 mAb in New Zealand white rabbits (NZWs), a 5 mg dose was administered 4 or 8 h after challenge with 10 LD50. The results indicated that 5 mg of HZ45 could treat the NZWs within 8 h after exposure to 10 LD50 botulinum. Consequently, in an in vivo context, including mice and rabbits, HZ45 mAb could protect against botulinum type A intoxication.

29 September 2024 in Vaccines
Verified
Journal Article
Open access
PDF file
HYHyeongseok Yun
Hyeongseok Yun
HJHAE EUN JOE
HAE EUN JOE
DSDong Hyun Song
Dong Hyun Song
YSYoung-Jo Song
Young-Jo Song
SHSunghyun Hong
Sunghyun Hong
CYChi Ho Yu
Chi Ho Yu
Background: Ricin, a toxin extracted from the seeds of Ricinus communis, is classified as a ribosome-inactivating protein. The A-subunit of ricin shows RNA N-glycosidase activity that cleaves ribosomal RNA (rRNA) and exhibits toxicity by inhibiting protein synthesis and inducing vascular leak syndrome. Methods: In this study, we created a truncated version of the previously developed R51 ricin vaccine (RTA 1-194 D75C Y80C) through in silico analysis. Results: The resulting R51-3 vaccine showed a more-than-six-fold increase in soluble protein expression when compared to R51, with over 85% solubility. In a pilot toxicity test, no toxicity was observed in hematological and biochemical parameters in BALB/c mice and New Zealand white rabbits following five repeated administrations of R51-3. Furthermore, R51-3 successfully protected mice and rabbits from a 20 × LD50 ricin challenge after three intramuscular injections spaced 2 weeks apart. Similarly, monkeys that received three injections of R51-3 survived a 60 µg/kg ricin challenge. Conclusions: These findings support R51-3 as a promising candidate antigen for ricin vaccine development.